REAL-WORLD EVIDENCE THAT CAN'T BE REPLICATED
With 5 approved biosimilars, and more in development, we're fully committed to the long-term success of biosimilars.
products, including therapeutic and supportive care
including biosimilars, for more than a decade* through natural disasters and during
of lives covered—unrestricted, with no step edit required for KANJINTI® and MVASI®†
with Amgen Biosimilars‡
countries in the manufacturing and distribution network
by Amgen Assist 360™ for MVASI® and KANJINTI®§
EXPLORE OUR VIDEOS ON BIOSIMILARS
My Experience With Biosimilars
Watch Lee Schwartzber, MD, FACP, and Chris Marcum, PharmD, share their experiences with biosimilars.
Supply Shortages in Oncology
Watch Chris Marcum, PharmD, talk about why reliable drug supply is critical in oncology.
QUALITY FAST FACTS
Watch a high-level overview of ensuring the quality of biosimilars.
EFFICACY FAST FACTS
Watch an overview of efficacy as it relates to biosimilars.
*From American Society of Health System Pharmacists: ongoing data monitoring (2007-2017) (2019-2021); FDA (2018-2020).
†From MMIT coverage in February 2021 for KANJINTI® and MVASI®. Covered is defined as covered with no step edit. The data represent plan participants enrolled in commercial and Medicare Advantage plans.
‡Based on global data, and includes an inflammation biosimilar.
§As of March 2021.